PERSPECTIVA HISTÓRICA DE LA ONCOLOGÍA GASTROINTESTINAL

  • Leonardo Rojas Clínica Colsanitas
Palabras clave: Tumor, neoplasia, gastrointestinal, historia

Resumen

La historia de la oncología gastrointestinal está atada a la de la oncología en general. Desde los primeros conocimientos sobre la enfermedad, pasando por los desarrollos de las técnicas quirúrgicas hasta el conocimiento de la fisiopatología celular y molecular, la oncología gastrointestinal muestra el desarrollo que han tenido las distintas disciplinas para el entendimiento y control del cáncer. Las mejoras en la detección temprana han tenido de igual forma impacto trascendental no solo en los resultados sino en el entendimiento y el abordaje la patología gastrointestinal oncológica. La historia de la oncología gastrointestinal está muy influenciada por el desarrollo del conocimiento y tratamiento de dos enfermedades: el cáncer colorrectal y el cáncer gástrico, varios de sus avances son la base del abordaje de las distintas neoplasias del tracto gastrointestinal e incluso de otros tumores de distinto origen.

Biografía del autor/a

Leonardo Rojas, Clínica Colsanitas
Departamento de oncología clínica. Clínica Colsanitas. Bogotá, Colombia.

Citas

1. Mulcahy HE, Hyland J, O’Donoghue DP. From dinosaurs to DNA: a history of colorectal cancer. Int J Colorectal Dis. 2003;18(3):210-215.
2. Menendez P, Padilla D, Villarejo P, Menendez JM, Rodriguez Montes JA, Martin J. [Historical aspects of neoplastic diseases: colorectal cancer]. Gastroenterol Hepatol. 2010;33(7):541-546.
3. Vargas A, López M, Lillo C, Vargas MJ. [The Edwin Smith papyrus in the history of medicine]. Rev Med Chil. 2012;140(10):1357-1362.
4. Sánchez Gonzales MA. Historia, teoría y método de la medicina: introducción al pensamiento médico. Barcelona 1998.
5. Gallucci BB. Selected concepts of cancer as a disease: from 1900 to oncogenes. Oncol Nurs Forum. 1985;12(5):69-78.
6. Tan SY, Yeow ME. John Hunter (1728 - 1793): founder of scientific surgery. Singapore Med J. 2004;45(5):196- 198.
7. Galler AS, Petrelli NJ, Shakamuri SP. Rectal cancer surgery: a brief history. Surg Oncol. 2011;20(4):223- 230.
8. Lange MM, Rutten HJ, van de Velde CJ. One hundred years of curative surgery for rectal cancer: 1908-2008. Eur J Surg Oncol. 2009;35(5):456-463.
9. Cotlar AM. Historical landmarks in operations on the colon--surgeons courageous. Curr Surg. 2002;59(1):91-95.
10. Hajdu SI. A note from history: Rudolph Virchow, pathologist, armed revolutionist, politician, and anthropologist. Ann Clin Lab Sci. 2005;35(2):203-205.
11. Zhang CD, Yamashita H, Seto Y. Gastric cancer surgery: historical background and perspective in Western countries versus Japan. Ann Transl Med. 2019;7(18):493.
12. Groves EW. On the Radical Operation for Cancer of the Pylorus: With Especial Reference to the Advantages of the Two-Stage Operation and to the Question of the Removal of the Associated Lymphatics. Br Med J. 1910;1(2563):366-370.
13. Cattell RB, Mosely CH. Combined resection of the stomach and transverse colon for carcinoma; report of two cases. Lahey Clin Bull. 1946;4(8):238-241.
14. Brunschwig A. Pancreato-total gastrectomy and splenectomy for advanced carcinoma of the stomach. Cancer. 1948;1(3):427-430.
15. Lawrence W, Jr., McNeer G. An analysis of the role of radical surgery for gastric cancer. Surg Gynecol Obstet. 1960;111:691-696.
16. DeVita VT, Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-8653.
17. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238(23):787-793.
18. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663-666.
19. Poon MA, O’Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7(10):1407-1418.
20. Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with highdose folinic acid: a pilot study. Cancer Treat Rep. 1982;66(10):1803-1807.
21. Madajewicz S, Petrelli N, Rustum YM, et al. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 1984;44(10):4667-4669.
22. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879-1887.
23. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939-944.
24. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15(2):808-815.
25. Kidani Y, Noji M, Tashiro T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gan. 1980;71(5):637-643.
26. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987;47(22):5944-5947.
27. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275-288.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
29. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983;80(5):1337-1341.
30. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992- 3995.
31. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408- 1417.
32. Dobosz P, Dzieciatkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019;10:2965.
33. Decker WK, da Silva RF, Sanabria MH, et al. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2017;8:829.
34. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154-158.
35. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):268-273.
36. Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009;69(2):383-392.
37. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010- 1015.
38. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371-1378.
39. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823-830.
40. Kardinal CG, Yarbro JW. A conceptual history of cancer. Semin Oncol. 1979;6(4):396-408. 41. Gomez P, Rosado A. History of cancer investigation. Arch Invest Med (Mex). 1981;12(3):361-375.
Publicado
2021-02-12
Sección
Perspectiva del diagnóstico y Tratamiento del Cancer